Evidence map›Paper›PMID 41200633›Full record

ArticleCureus2025

Incidence and Predictors of Pulmonary Embolism Recurrence and Mortality in Patients With Lung Cancers.

Reem F Almesfir, Nada F Alqubaibi, Ahmed Alkhelaifi, Abdel Galil Abdel Gader, Fahad A Aleidan

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Reem F AlmesfirMedical Oncology, King Abdulaziz Medical City, Health Affairs, Ministry of National Guard, Riyadh, SAU.
Nada F AlqubaibiObstetrics and Gynaecology, King Faisal Specialist Hospital and Research Centre, Riyadh, SAU.
Ahmed AlkhelaifiOrthopedics, King Abdulaziz Medical City, Health Affairs, Ministry of National Guard, Riyadh, SAU.
Abdel Galil Abdel GaderMedicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.
Fahad A AleidanMedicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Pulmonary embolism (PE) is a serious and potentially fatal complication in lung cancer patients. This study aims to identify predictors of recurrent PE and related mortality in this population. Methods A retrospective review was conducted using electronic medical records from King Abdulaziz Medical Cities in Riyadh and Jeddah, Saudi Arabia. Lung cancer patients with confirmed initial PE were included. Data on demographics, clinical features, and laboratory values-including Eastern Cooperative Oncology Group (ECOG) performance status, systemic infections, serum albumin, and D-dimer levels-were collected. PE and its recurrence were confirmed by standard imaging techniques. The statistical analyses comprised descriptive statistics, analysis of the receiver operating characteristic (ROC) curve to establish the optimum cutoff values of the biomarkers, and logistic regression to identify predictors of PE recurrence and mortality. Results A total of 98 adult lung cancer patients with initial PE were identified. Of these, 19 (19.4%) experienced recurrent PE, with a mortality rate of 73.7% in this group. Recurrent PE was significantly associated with poor ECOG performance status and systemic infections. Laboratory findings showed that recurrent cases had lower serum albumin (≤ 20.5 mg/L) and higher D-dimer (≥ 6.5 mg/L) levels. Logistic regression revealed that adenocarcinoma type, systemic infection, elevated D-dimer, and low albumin were significant predictors of PE recurrence. Mortality was higher in the recurrence group compared to non-recurrence (73.7% vs. 44.3%, p = 0.021). Conclusion Recurrent PE occurs in 19.4% of lung cancer patients with initial PE and carries high mortality. Identified predictors warrant validation in larger studies.

Indexed as

d-dimerlung cancerpredictorspulmonary embolismserum albumin

Identifiers

PMID41200633
PMCPMC12588363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.